- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | Telomir-1 shows anti-aging effects in progeria cell study | 2 | Investing.com | ||
| 18.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging | 187 | ACCESS Newswire | Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals... ► Artikel lesen | |
| 18.06. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.06. | EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria | 2 | Benzinga.com | ||
| 11.06. | Telomir-1 zeigt vielversprechende Ergebnisse bei der Umkehrung von Morbus-Wilson-Symptomen | 7 | Investing.com Deutsch | ||
| 11.06. | Telomir-1 shows promise in reversing Wilson's disease symptoms | 3 | Investing.com | ||
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 11.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model | 237 | ACCESS Newswire | Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival.Building on... ► Artikel lesen | |
| 05.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome | 228 | ACCESS Newswire | Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential... ► Artikel lesen | |
| 05.06. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 05.06. | EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder | 4 | Benzinga.com | ||
| 02.06. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform | 168 | ACCESS Newswire | Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026 MIAMI, FL / ACCESS Newswire / June 2, 2025... ► Artikel lesen | |
| 29.05. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration Animal Model Using FDA-Recognized Surrogate Endpoints | 282 | ACCESS Newswire | A unique oral drug candidate that is shown to restore vision and regenerate the retina in an animal model, addressing a major unmet need in ocular therapeutics MIAMI, FLORIDA / ACCESS Newswire / May... ► Artikel lesen | |
| 29.05. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 21.05. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND | 179 | ACCESS Newswire | Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1's upcoming IND submission for a rare disease indication MIAMI, FLORIDA / ACCESS Newswire... ► Artikel lesen | |
| 21.05. | EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND | 7 | Benzinga.com | ||
| 15.05. | Telomir unveils new drug candidate against resistant bacteria | 3 | Investing.com | ||
| 15.05. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity | 170 | ACCESS Newswire | Antimicrobial resistance is recognized as one of the top global public health threats, and Telomir-Ag2 strengthens Telomir's pipeline with a differentiated candidate designed to address this urgent... ► Artikel lesen | |
| 15.05. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | Telomir Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.05. | Telomir-1 zeigt vielversprechende Ergebnisse in präklinischer Studie zur zellulären Alterung | 4 | Investing.com Deutsch |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| MODERNA | 23,305 | +0,17 % | Laboratorios Rovi: FDA approves Moderna vaccine for RSV in adults aged 18 to 59 | ||
| VALNEVA | 2,420 | -0,49 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
| BAVARIAN NORDIC | 22,640 | -0,70 % | Bavarian Nordic A/S: Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women | First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable... ► Artikel lesen | |
| VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
| GERON | 1,334 | +5,12 % | Geron Corp. Posts Narrower Loss In Q1 | WASHINGTON (dpa-AFX) - Geron Corp. (GERN) posted a first quarter net loss of $19.8 million, or $0.03 per share, compared to a loss of $55.4 million, or $0.09 per share, prior year. Total net... ► Artikel lesen | |
| IMMUNITYBIO | 2,300 | -0,09 % | ImmunityBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ZAI LAB LTD ADR | 31,600 | +6,04 % | ZAI LAB (09688): RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE | ||
| VERASTEM | 3,560 | 0,00 % | XFRA 2VSA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 15,634 | +5,08 % | Swedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases | STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating... ► Artikel lesen | |
| GRAIL | 40,100 | -2,91 % | Medical Care Technologies Inc.: The Grail Collection: MDCE's Infinite Auctions is Back on Track and Set to Showcase High Value Memorabilia at Auction | Medical Care Technologies' Infinite Auctions is Set to Reach for the Record Books with High End Memorabilia Sales. MESA, AZ / ACCESS Newswire / June 25, 2025 / Infinite Auctions, a premier online auction... ► Artikel lesen | |
| ANNOVIS BIO | 1,782 | -1,22 % | Annovis Bio Inc.: Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance | MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| XENON PHARMACEUTICALS | 27,000 | -2,88 % | Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VANCOUVER, British Columbia and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing... ► Artikel lesen | |
| BICYCLE THERAPEUTICS | 6,200 | 0,00 % | Bicycle Therapeutics plc: Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on June 2, 2025, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting... ► Artikel lesen |
Das Unternehmen TELOMIR PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,560 Euro und damit -8,24 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.